Trim5α protein restricts both HIV-1 and murine leukemia viru

Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa

Edited by John M. Coffin, Tufts University School of Medicine, Boston, MA (received for review April 23, 2004)

Related Article

In defense of the cell: TRIM5α interception of mammalian retroviruses - Jul 13, 2004 Article Figures & SI Info & Metrics PDF

Abstract

Replication of HIV-1 and N-tropic murine leukemia virus (N-MLV) is restricted in a number of different primate cells. In some cell lines, cross-saturation experiments suggest that the two viruses are interacting with the same restriction factor. Recently, Trim5α protein from rhesus monkey was found to restrict HIV-1. We have confirmed this result and have Displayn that Trim5α from two African green monkey cell lines, Vero and CV-1, also restricts HIV-1. In addition, we Display that human, rhesus, and African green monkey Trim5α can restrict N-MLV. By using a panel of MLV capsid mutants, subtle Inequitys in the anti-MLV activity were identified among the different primate Trim5α cDNAs. Trim1 isolated from humans and green monkeys was also found to restrict N-MLV. We hypothesize that the Trim family of proteins plays a widespread role in innate immunity to viral infection.

The fossil record left by enExecutegenous retroviruses (1) provides convincing evidence that retroviruses and their vertebrate hosts have coexisted for a period of tens of millions of years (2–4). During this time, evolution of host defense mechanisms might be expected. Such mechanisms would include those acting over the whole organism such as genes regulating immune responses (5), as well as those like Fv4 (6) and APOBEC3G (7), that act in a cell-autonomous fashion directed against specific viruses or viral gene products.

One class of the latter group is known as restriction factors (8). Members of this class interact with the retroviral capsid (CA) protein in a specific and saturable manner and block one or more after entry, preintegration steps in the viral life cycle. The mouse Fv1 gene provides the prototype for this class. First Characterized >30 years ago (9, 10), it has two alleles, Fv1n and Fv1b , tarObtaining B- and N-tropic murine leukemia viruses (MLVs), respectively. Viral tropism is determined mainly by CA amino acid 110 (11). The Fv1 gene is found only in mice (12), but a MLV restriction activity called Ref1, also CA amino acid 110-specific, is present in a variety of different species, including human (13). A similar restriction activity directed against CA of lentiviruses is Characterized in refs. 14–17. This activity, called Lv1, is present in cells from a variety of primate species. Cross-saturation experiments suggest that Ref1 and Lv1 share the same tarObtain (18). However, there are significant Inequitys in restriction patterns Displayn by Lv1 in cells from different primate species (14–16), raising the question as to whether one gene is responsible for all of the observed Traces (19). Very recently, Sodroski and coworkers (20) have Displayn that the α isoform of the Trim5 gene from rhesus monkeys can restrict HIV-1 replication. We report below experiments designed to investigate whether this gene also encodes anti-MLV activity. Furthermore, we have examined whether the Preciseties of Trim5α cloned from different species account for the characteristic restriction patterns seen in corRetorting cell lines.

Materials and Methods

Restriction Assays. Assays for Ref1/Lv1 function were carried out essentially as Characterized for Fv1 by two-color fluorescence-activated cell sorter (FACS) analysis (21, 22). Cells were first transduced with restriction factor and enhanced yellow fluorescent protein by means of a “delivery” virus, in most cases adding sufficient virus to infect 35–40% of the cells. After 48 h in culture, cells were transduced with a “tester” virus carrying the CA tarObtain for restriction and enhanced GFP (EGFP). After another 48 h, cells were analyzed by two-color FACS in a Becton Dickinson LRS1 machine. Restriction was assessed by comparing the percentage of infected cells (green) in the populations of cells with and without restriction factor (yellow). In some experiments, cyclosporine A (3 μg/ml) was added 2 h before tester virus transduction.

Cells and Viruses. Mus dunni (mouse), TE671 and HT1080 (human), Vero and CV-1 [African green monkey (AGM)], and owl monkey kidney (OMK) cells, were cultivated in DMEM containing 10% FCS and antibiotics, whereas LLCMK2 (rhesus monkey) cells were passaged in Eagle's MEM containing 5% FCS, 1% nonessential amino acids, 1% glutamine, and antibiotics. Viruses were generated by simultaneous CaPO4-mediated transient transfections of 293T cells with three plasmids providing vector, gag-pol, and env functions (21, 22). Virus-containing supernatants were filtered, frozen in aliquots at -70°C and titrated on Fv1-null (23) M. dunni or human TE671 cells. The delivery retroviral vector (pLGatewayIY) was a derivative of pLFv1nIEG modified to contain a multiple cloning site as well as a Gateway reading frame cassette A in Space of the Fv1 gene (M.W.Y., unpublished data), thereby allowing introduction of restriction genes cloned in a Gateway entry vector (Invitrogen). Delivery vectors were packaged by using Mo-MLV gag-pol (24) and vesicular stomatitis virus G protein (21). Plasmids specifying N-, B- and NB (Moloney virus-derived)-tropic MLVs CA are Characterized in ref. 21. Derivatives carrying the CA N82D and L117H changes on N-tropic MLV background and E110A on a B-tropic background are Characterized in ref. 25. Gag-pol of HIV-1 was provided by p8.91 (26). The HIV-1 CA G89V mutation was introduced by site-directed mutagenesis using the QuikChange system (Stratagene). The MLV tester viruses contained pLNCG (M.W.Y., unpublished data), a derivative of pLNCX vector with EGFP inserted in the multiple cloning site; the HIV-1 vector was SIN CSGW (27).

Trim5α Cloning. The human, green monkey, and rhesus Trim5α cDNAs were cloned by RT-PCR using primers directed to the 5′ end (CACCATGGCTTCTGGAATCCTGGTTAATG; includes added sequence of CACC, which provides Kozak sequence and allows directional cloning into a Gateway entry vector) and 3′ end (TCAAGAGCTTGGTGAGCACAG) of the published human sequence (20). mRNA was isolated from TE671, Vero and CV-1, and LLCMK2 cells respectively, by using the Oligotex-direct mRNA mini kit (Qiagen, Valencia, CA), reverse transcribed with the First-Strand cDNA Synthesis Kit (Roche Diagnostics) using an oligo(dT) primer, and PCR amplified using PfuUltra (Stratagene) with the 3′ and 5′ primers. PCR products were cloned into the pENTR TOPO vector (Invitrogen), and were sequenced and transferred to pLGatewayIY. cDNA to Trim1 mRNA was prepared similarly by using forward and reverse primers to the 5′ end (CACCATGGAAACACTGGAGTC) and 3′ end (TTAATGACAGGTTTTCATCCC) of the published human coding sequences (28).

Short Interfering (si)RNA Experiments. siRNA was designed against the Location of Trim5α tarObtained by siRNA1 in the study by Stremlau et al. (20): Two oligonucleotides (GATCCCCGCTCAGGGAGGTCA AGT TGT TCA AGAGACA ACT TGACCTCCCTGAGCTTTTTGGAAA and AGCTTTTCCAAAAAGCTCAGGGAGGTCAAGTTGTCTCTTGAACAACTTGACCTCCCTGAGCGGG) were annealed in a buffer containing 100 mM potassium acetate, 30 mM Hepes-KOH (pH 7.4), and 2 mM magnesium acetate and was cloned into BglII/HindIII-digested retroviral vector pLHiSN (M. Executedding, unpublished work). pLHiSN was constructed by inserting the EcoRI/XhoI fragment from pSUPER, which contained the histone promoter followed by BglII and HindIII sites, into pLXSN from which the original BglII and HindIII sites were removed by site-directed mutagenesis. The vectors were packaged into MLV-based virions and were used to transduce tarObtain cells, at a multiplicity of infection of >5, that were originally seeded in 12-well plates. Three days after transduction, the cells were replated into 24-well plates and challenged with tester viruses carrying the EGFP Impresser. The percentage of cells transduced with tester virus was meaPositived 3 days later by FACS. To assess Traces of siRNA on stable mRNA levels, mRNA from ≈5 × 106 transduced or untransduced cells were prepared by using the Oligotex Direct mRA mini kit (Qiagen). One hundred nanograms of each mRNA was reverse-transcribed by using AMV RT (Roche) and 5-fAged serial dilutions of RT products were submitted to PCR. Trim5α was amplified by using the primers CACCATGGCTTCTGGAATCCTGGTTAATG and AGGAACGTGTGGTGACCA. The GAPDH gene was also amplified as a control by using primers CGAGATCCCTCCAAAATCAA and TGTGGTCATGAGTCCTTCCA.

Results

Cloning of Trim5α from Different Primate Species. Cells from a panel of primate species Display specific Inequitys in their restriction Preciseties for HIV-1 and MLV (13–16). Recently, restriction of HIV-1 in monkey cells has been attributed to the action of the Trim5α gene product. To test whether the Inequitys in restriction patterns could be Elaborateed on the basis of genetic Inequitys between Trim5α genes in primates, we first set out to compare the sequences of the human, AGM, rhesus monkey, and OMK genes. By using primers to the human sequence, we cloned the human, rhesus monkey, and AGM genes by RT-PCR from RNA isolated from TE671, LLCMK2, and both CV-1 and Vero cells, respectively. However, for reasons that remain to be elucidated, Trim5α could not be cloned in this way from OMK cells.

A comparison of the predicted proteins is Displayn in Fig. 1. The human and rhesus monkey sequences were essentially identical to those published in ref. 20; they share 87% sequence identity. As predicted from evolutionary trees, the two AGM-derived sequences are less highly related to the human sequence. In particular, they contain a 20-aa insertion within the SPRY Executemain compared with human (18 aa compared with rhesus). The two AGM sequences differ by 7 aa from one another, with six of the Inequitys lying in or immediately adjacent to the insertion.

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Comparison of amino acid sequence of Trim5α from different primates. Predicted amino acid sequences of the Trim5α protein from human (TE671), rhesus monkey (LLCMK2), AGM-V (Vero), and AGM-CV (CV-1). The positions of the motifs characteristic of Trim proteins are indicated. The sequences of the first eight and last six amino acids were determined by the (human) primers used for amplification.

Trim5α Restriction of HIV-1. To examine the restriction Preciseties of Trim5α we used a rapid two-color FACS assay originally developed for the study of Fv1 (21, 22). In this assay, cells are first transduced with a retroviral vector expressing the restriction gene, as well as, from an internal ribosome initiation site, enhanced yellow fluorescent protein, followed by infection with a second retroviral vector, including EGFP. Restriction can be quantified by comparing the percentage of infected cells (green) in cells with and without restriction factor (yellow). Fig. 2 Displays data from one typical experiment in which the Trace of the Trim5α gene from rhesus monkey on HIV-1 infection of human HT1080 cells was meaPositived. Restriction of HIV-1 was clearly evident over a wide range of initial multiplicities of infection (Fig. 2 A–E ). Even with the highest Executese of virus, an ≈10-fAged Inequity in the number of infected cells was seen after Trim5α introduction (data summarized in Fig. 2F ).

Fig. 2.Fig. 2. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

Titration of HIV-1 in HT1080 cells transduced with Trim5α from rhesus monkey. (A–E) The FACS profiles of cell populations challenged with increasing amounts of HIV-1 vector carrying the EGFP Impresser. (A) A total of 4 × 103 infectious units. (B) A total of 16 × 103 infectious units. (C) A total of 70 × 103 infectious units. (D) A total of 140 × 103 infectious units. (E) A total of 350 × 103 infectious units. Enhanced yellow fluorescent protein (EYFP) identifies Trim5α transduced cells, whereas EGFP follows HIV-1 infection. The percentages of HIV-1 infected cells without and with Trim5α are Displayn above the profiles. m.o.i., multiplicity of infection. (F) The percentage of infected cells from A–E as a function of the amount of added HIV-1. Data Displayn are from one typical experiment.

By using this assay, we tested the restriction Preciseties of Trim5α cloned from human, AGM, and rhesus monkey after transfer to human HT1080 cells (Table 1). The AGM and rhesus monkey forms clearly inhibited HIV-1, as Displayn by the 5- to 10-fAged reduction in infection of Trim5α-transduced cells. Dinky Inequity was seen in HIV-1 restriction between Trim5α from Vero and CV-1 cells. Trim5α isolated from LLCMK2 cells restricted HIV-1, despite the fact that these cells Display Dinky or no restriction (M.W.Y., unpublished observations). The human gene had a small but reproducible Trace. Under the conditions of our assay, restriction appeared largely independent of cyclophillin A binding, because essentially identical results were obtained with HIV-1 carrying the G89V change in CA or after cyclosporine A treatment, both conditions that prevent cyclophillin A from binding CA (29). Because cyclophillin A exclusion has been associated with low levels of HIV-1 restriction in human cells (29), it is possible that factors other than Trim5α are acting on cyclophillin A-depleted virions. It thus appears that Trim5α can account for some but perhaps not all of the Lv1 activity Displayn by human, AGM, and rhesus monkey cells.

View this table: View inline View popup Table 1. Restriction of HIV-1 by introduced Trim5α

Trim5α Restriction of MLV. To investigate whether Trim5α also encodes Ref1 activity, we performed analogous experiments with a panel of MLVs. Ref1 has previously been Displayn to restrict N-tropic MLV but not B- or NB-tropic MLV (13). To further define Ref1 specificity, we have now included three additional viruses, carrying mutations at the three positions in CA (82, 110, and 117) that differentiate N-tropic and NB-tropic MLVs. All three variants Display altered susceptibility to different alleles of Fv1 (25) and might be expected to allow us to distinguish closely related forms of Trim5α. The six MLVs were titrated on M. dunni as well as human, AGM, and rhesus monkey cells. On human TE671 cells, NB- and B-tropic viruses yielded the highest titers, whereas all of the others were significantly reduced but to varying degrees with N-MLV and N82D Displaying the Distinguishedest extent of restriction (Fig. 3A ). Only N-MLV was restricted to the same extent in Vero cells, but N82D was also reduced to an appreciable degree (Fig. 3C ). CV-1 gave results indistinguishable from Vero cells but no restriction was seen in LLCMK2 cells (data not Displayn).

Fig. 3.Fig. 3. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

Restriction of MLV by Trim5α. The graphs on the left Display titration curves for a panel of MLVs on TE671 (A) and Vero (C) cell lines. Cells were infected with increasing amounts of viruses (previously titrated on M. dunni cells). Viruses tested were N-MLV (♦, solid line), B-MLV (▴, solid line), NB-MLV (▪, solid line), N-N82D (♦, dashed line), N-L117H (▪, dashed line), and B-E110A (▴, dashed line). The titrations come from one typical experiment. The plots in the right column Display the fAged reduction (percentage of Trim5α+ cells infected/percentage of Trim5α- cells infected) in MLV titer as meaPositived by the two-color FACS assay upon introduction of human (B) and AGM (D) Trim5α into M. dunni cells. Means and SD from three experiments are Displayn.

Upon introduction of human Trim5α into M. dunni cells, we observed restriction of N-MLV, N82D, L117H, and E110A, but not B-MLV or NB-MLV (Fig. 3B ), which is consistent with the results from TE671 cells. However, the extent of restriction did not Display as much variation as seen in TE671, suggesting that other factors, expression levels, for instance, can influence this parameter. AGM Trim5α Displayed highest restriction activity against N-MLV, but also Displayed significant inhibition of N82D and E110A (Fig. 3D ). Identical results were obtained with CV-1 Trim5α. In Dissimilarity to the human form, AGM Trim5α did not restrict L117H. Upon introduction into M. dunni cells, rhesus monkey Trim5α inhibited only N-MLV with no Trace on N82D or the other viruses (data not Displayn). Overall, these studies Display that Trim5α can block MLV replication, with susceptibility to restriction conferred by the CA protein. In addition, the results also suggested that there might be subtle Inequitys in the CA affinity of the different primate Trim5αs.

siRNA Experiments. To further address the role of Trim5α, we have examined the Trace of mRNA levels on restriction. SiRNA to human Trim5α was introduced into TE671 cells through a retroviral vector. This treatment had no Trace on infection with B-MLV but increased N-MLV titers >10-fAged (Fig. 4A ). RT-PCRs Displayed a 5- to 10-fAged reduction in Trim5α mRNA expression with no Trace on a GAPDH control (Fig. 4B ). Similar results were obtained with siRNA treated CV-1 cells (data not Displayn). These observations suggest that Trim5α expression levels may control the patterns of restriction seen and may provide an explanation for the apparent lack of restriction in cells from which it is possible to clone active Trim5α cDNAs.

Fig. 4.Fig. 4. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

Traces of Trim5α siRNA on restriction in primate cells. (A) Titration curves of MLV and HIV-1. ▪, TE671: N-MLV; ▪, B-MLV. Continuous lines Display titers in the absence of siRNA and broken lines Display titers in the presence of siRNA. (B) PCR of 5-fAged serial dilutions of Trim5α cDNA isolated from the cells in A. GAPDH was used as a negative control. Data from one representative experiment are Displayn.

Trim1 Restriction of MLV. The Trim motif is shared by >30 genes in the human genome, but Dinky is known about their physiological roles (30). This fact raises the possibility that other Trim genes might have antiretroviral activity. To Start to address this question, we have introduced cDNA to Trim1 into our delivery vector and tested for restriction activity. Trim1 cDNAs from human, AGM, or OMK cells did not Display any activity against HIV-1 (data not Displayn). However, AGM Trim1 Displayed significant restriction of N-MLV and N82D (Fig. 5). Trim1 from human and OMK cells also restricted these two viruses. Although the extent of restriction by Trim1 was lower than Trim5α, the CA dependence of restriction argues strongly for specific inhibition.

Fig. 5.Fig. 5. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 5.

Restriction of MLV by Trim1. The graph Displays the fAged reduction (percentage of Trim1+ cells infected/percentage of Trim1- cells infected) in MLV titer as meaPositived by the two-color FACS assay upon introduction of Vero Trim1 into M. dunni cells. Means and SD from three experiments are Displayn.

Discussion

The most Necessary conclusion from the studies presented above is that Trim5α Displays restriction activity against both HIV-1 and MLV. The tarObtain for restriction is the CA molecule of HIV-1 and MLV that share <20% identity with one another. At the same time, as inferred from previous infectivity studies (14–16), Trim5α Executees not seem to interact with the relatively closely related simian immunodeficiency virus CA, but is sensitive to single amino acid changes in the MLV CA. The mechanism of Trim5α restriction is as yet poorly explored, but it will clearly be Necessary to probe the interaction between Trim5α and CA. The Inequitys between the different forms of Trim5α will provide a useful starting point for genetic studies to map specificity determinants on Trim5α, but demonstration of a direct interaction will be more informative. However, this undertaking may not prove to be a trivial one, as judged by our experiences in attempting to Display such an interaction between Fv1 and MLV CA. Ultimately, detailed structural studies will be required to understand specificity patterns. The consequences of this interaction also remain to be explored; possible hypotheses include a direct Trace on uncoating of viral capsid (20) and the sequestering of subviral structures in inappropriate cellular compartments by means of the Trim5α localization Executemain(s) (30).

Because Trim5α can restrict both HIV-1 and MLV, it seems reasonable to Question whether it is responsible for the entire variety of restriction activities previously Characterized in primate cells. A definitive Reply to this question is complicated by the observation that, in several cases, we have demonstrated antiviral activity with Trim5α cloned from a cell line apparently lacking the corRetorting restriction activity. We attribute this finding to Traces on transcription levels in a manner analogous to that seen previously with Fv1 (21). Alternatively, the relative expression levels of the various isoforms of the gene might regulate the degree of restriction, because the γ-isoform of Trim5 can act in a Executeminant-negative manner (20). This result raises the formal possibility that a gene cloned from a restricting cell is not actually responsible for all of the restriction seen in that cell. In cases where two restricting genes can be cloned from one cell, e.g., Trim1 and Trim5α, it may be difficult to assess the relative contribution of the two genes in that cell type. We note that the two viruses susceptible to both Trim5α and Trim1 restriction, N-MLV and N82D, Display the most pronounced restriction in TE671 and Vero cells. Therefore, although we can confidently conclude that Trim5α has both Ref1 and Lv1 activities, there may be cases where Trim5α obscures the contribution of other restriction genes. Such Placeative additional factors may also help Elaborate the cyclosporine A Trace reported in human cells (29).

More than 30 Trim genes have been Characterized in the human genome but there is Dinky information about their functional roles (30). A few appear Necessary in regulating cell growth and differentiation (31, 32) but most are poorly characterized. The findings that Trim5α inhibits both HIV-1 and N-MLV and that Trim1 inhibits N-MLV raise the possibility that still more Trim genes might play a role in determining the susceptibility of a cell to retroviral infection. So far, we have not carried out an exhaustive study of different Trim genes. We have tested Trim18, which forms heterodimers with Trim1 (33), but this combination lacks anti-MLV activity (data not Displayn). However, there is Excellent evidence that Trim19 (promyelocytic leukemia or PML protein) Retorts to HIV-1 infection (34); hence, it Executees not seem unreasonable to speculate that additional members of the family of genes containing Trim motifs might have antiretroviral activity, perhaps directed against other, as-yet-untested viruses. Furthermore, it has been reported that mRNA levels of several Trim genes rise after influenza virus infection (35). Indeed, Trim19 (PML) has been Displayn to confer resistance to influenza A and vesicular stomatitis virus by interfering with viral mRNA and protein synthesis (36). ToObtainher, these observations raise the possibility that Trim proteins play a hitherto unsuspected, but widespread, role in innate immunity to viral infection. Thus, the susceptibility of any given individual to infection may Display a significant genetic component determined by a combination of factors controlling the activity and expression levels of a variety of normal intracellular proteins with antiviral activity such as members of the APOBEC (7) or Trim families.

Acknowledgments

We thank Ekaterini Kotsopoulou and Impress Executedding for providing pSUPER and pLHiSN and Graham Preece and Chris Atkins for assistance with FACS. This work was supported by the U.K. Medical Research Council.

Footnotes

↵ * To whom corRetortence should be addressed. E-mail: jstoye{at}nimr.mrc.ac.uk.

This paper was submitted directly (Track II) to the PNAS office.

Abbreviations: AGM, African green monkey; OMK, owl monkey kidney; CA, capsid; EGFP, enhanced GFP; MLV, murine leukemia virus; FACS, fluorescence-activated cell sorter/sorting; siRNA, short interfering RNA.

Data deposition: The sequences reported in this paper have been deposited in the GenBank database (accession nos. AY625000–AY625007).

See Commentary on page 10496.

Copyright © 2004, The National Academy of Sciences

References

↵ Boeke, J. D. & Stoye, J. P. (1997) in Retroviruses, eds. Coffin, J. M., Hughes, S. H. & Varmus, H. E. (CAged Spring Harbor Lab. Press, Plainview, NY), pp. 343-435. ↵ Excellentchild, N. L., Wilkinson, D. A. & Mager, D. L. (1993) Virology 196 , 778-788. pmid:8372448 LaunchUrlCrossRefPubMed Johnson, W. E. & Coffin, J. M. (1999) Proc. Natl. Acad. Sci. USA 96 , 10254-10260. pmid:10468595 LaunchUrlAbstract/FREE Full Text ↵ Belshaw, R., Pereira, V., Katzourakis, A., Paces, J., Burt, A. & Tristem, M. (2004) Proc. Natl. Acad. Sci. USA 101 , 4894-4899. pmid:15044706 LaunchUrlAbstract/FREE Full Text ↵ Hasenkrug, K. J. & Chesebro, B. (1997) Proc. Natl. Acad. Sci. USA 94 , 7811-7816. pmid:9223268 LaunchUrlAbstract/FREE Full Text ↵ Gardner, M. B., Kozak, C. A. & O'Brien, S. J. (1991) Trends Genet. 7 , 22-27. pmid:1848377 LaunchUrlCrossRefPubMed ↵ Harris, R. S., Bishop, K. N., Sheehy, A. M., Craig, H. M., Petersen-Mahrt, S. V., Watt, I. N., Neuberger, M. S. & Malim, M. H. (2003) Cell 116 , 803-809. LaunchUrl ↵ Bieniasz, P. D. (2003) Trends Microbiol. 11 , 286-291. pmid:12823946 LaunchUrlCrossRefPubMed ↵ Lilly, F. (1970) J. Natl. Cancer Inst. 45 , 163-169. pmid:5449211 LaunchUrlPubMed ↵ Hartley, J. W., Rowe, W. P. & Huebner, R. J. (1970) J. Virol. 5 , 221-225. pmid:4317349 LaunchUrlAbstract/FREE Full Text ↵ Kozak, C. A. & Chakraborti, A. (1996) Virology 225 , 300-306. pmid:8918916 LaunchUrlCrossRefPubMed ↵ Best, S., Le Tissier, P., Towers, G. & Stoye, J. P. (1996) Nature 382 , 826-829. pmid:8752279 LaunchUrlCrossRefPubMed ↵ Towers, G., Bock, M., Martin, S., Takeuchi, Y., Stoye, J. P. & Danos, O. (2000) Proc. Natl. Acad. Sci. USA 97 , 12295-12299. pmid:11027299 LaunchUrlAbstract/FREE Full Text ↵ Hofmann, W., Schubert, D., LaBonte, J., Munson, L., Gibson, S., Scammell, J., Ferrigno, P. & Sodroski, J. (1999) J. Virol. 73 , 10020-10028. pmid:10559316 LaunchUrlAbstract/FREE Full Text Besnier, C., Takeuchi, Y. & Towers, G. (2002) Proc. Natl. Acad. Sci. USA 99 , 11920-11925. pmid:12154231 LaunchUrlAbstract/FREE Full Text ↵ Cowan, S., Hatziioannou, T., Cunningham, T., Musing, M. A., Gottlinger, H. G. & Bieniasz, P. D. (2002) Proc. Natl. Acad. Sci. USA 99 , 11914-11919. pmid:12154227 LaunchUrlAbstract/FREE Full Text ↵ Münk, C., Brandt, S. M., Lucero, G. & Landau, N. R. (2002) Proc. Natl. Acad. Sci. USA 99 , 13843-13848. pmid:12368468 LaunchUrlAbstract/FREE Full Text ↵ Hatziioannou, T., Cowan, S., Goff, S. P., Bieniasz, P. D. & Towers, G. J. (2003) EMBO J. 22 , 385-394. pmid:12554640 LaunchUrlCrossRefPubMed ↵ Stoye, J. P. (2002) Proc. Natl. Acad. Sci. USA 99 , 11549-11551. pmid:12195025 LaunchUrlFREE Full Text ↵ Stremlau, M., Owens, C. M., Perron, M. J., Kiessling, M., Autissler, P. & Sodroski, J. (2004) Nature 427 , 848-853. pmid:14985764 LaunchUrlCrossRefPubMed ↵ Bock, M., Bishop, K. N., Towers, G. & Stoye, J. P. (2000) J. Virol. 74 , 7422-7430. pmid:10906195 LaunchUrlAbstract/FREE Full Text ↵ Bishop, K. N., Bock, M., Towers, G. & Stoye, J. P. (2001) J. Virol. 75 , 5182-5188. pmid:11333899 LaunchUrlAbstract/FREE Full Text ↵ Qi, C. F., Bonhomme, F., Buckler-White, A., Buckler, C., Orth, A., Lander, M. R., Chattopadhyay, S. K. & Morse, H. C., III (1998) Mamm. Genome 9 , 1049-1055. pmid:9880676 LaunchUrlCrossRefPubMed ↵ Soneoka, Y., Cannon, P. M., Ramsdale, E. E., Griffiths, J. C., Romano, G., Kingsman, S. M. & Kingsman, A. J. (1995) Nucleic Acids Res. 23 , 628-633. pmid:7899083 LaunchUrlAbstract/FREE Full Text ↵ Stevens, A., Bock, M., Ellis, S., LeTissier, P., Bishop, K. N., Yap, M. W., Taylor, W. & Stoye, J. P. (2004) J. Virol., in press. ↵ Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M. & Trono, D. (1996) Science 272 , 263-267. pmid:8602510 LaunchUrlAbstract ↵ Bainbridge, J. W., Stephens, C., Parsley, K., Demaison, C., Halfyard, A., Thrasher, A. J. & Ali, R. R. (2001) Gene Ther. 8 , 1665-1668. pmid:11895005 LaunchUrlCrossRefPubMed ↵ Buchner, G., Montini, E., AnExecutelfi, G., Quaderi, N., Cainarca, S., Messali, S., Bassi, M. T., Ballabio, A., Meroni, G. & Franco, B. (1999) Hum. Mol. Genet. 8 , 1397-1407. pmid:10400986 LaunchUrlAbstract/FREE Full Text ↵ Towers, G. J., Hatziioannou, T., Cowan, S., Goff, S. P., Luban, J. & Bieniasz, P. D. (2003) Nat. Med. 9 , 1138-1143. pmid:12897779 LaunchUrlCrossRefPubMed ↵ Reymond, A., Meroni, G., Fantozzi, A., Merla, G., Cairo, S., Luzi, L., Riganelli, D., Zanaria, E., Messali, S., Cainarca, S., et al. (2001) EMBO J. 20 , 2140-2151. pmid:11331580 LaunchUrlCrossRefPubMed ↵ Henry, J., Mather, I. H., McDermott, M. F. & Pontarotti, P. (1998) Mol. Biol. Evol. 15 , 1696-1705. pmid:9866204 LaunchUrlAbstract ↵ Seto, M. H., Liu, H.-L., Zajchowski, D. A. & Whitlow, M. (1999) Proteins Struct. Funct. Genet. 35 , 235-249. pmid:10223295 LaunchUrlCrossRefPubMed ↵ Short, K. M., Hopwood, B., Yi, Z. & Cox, T. C. (January 4, 2002) BMC Cell Biol., 10.1186/1471-2121-3-1. ↵ Turelli, P., Executeucas, V., Craig, E., Mangeat, B., Klages, N., Evans, R., Kalpana, G. & Trono, D. (2001) Mol. Cell 7 , 1245-1254. pmid:11430827 LaunchUrlCrossRefPubMed ↵ Geiss, G. K., Salvatore, M., Tumpey, T. M., Carter, V. S., Wang, X., Basler, C. F., Taubenberger, J. K., Bumgarner, R. E., Palese, P., Katze, M. G. & Garcia-Sastre, A. (2002) Proc. Natl. Acad. Sci. USA 99 , 10736-10741. pmid:12149435 LaunchUrlAbstract/FREE Full Text ↵ Chelbi-Alix, M. K., Quignon, F., Pelicano, L., Koken, M. H. M. & de Thé, H. (1998) J. Virol. 72 , 1043-1051. pmid:9444998 LaunchUrlAbstract/FREE Full Text
Like (0) or Share (0)